Seres Therapeutics (MCRB) Invested Capital (2016 - 2025)
Historic Invested Capital for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $43.7 million.
- Seres Therapeutics' Invested Capital rose 8268.74% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year increase of 8268.74%. This contributed to the annual value of $13.8 million for FY2024, which is 13072.94% up from last year.
- Per Seres Therapeutics' latest filing, its Invested Capital stood at $43.7 million for Q3 2025, which was up 8268.74% from $32.9 million recorded in Q2 2025.
- Seres Therapeutics' 5-year Invested Capital high stood at $175.7 million for Q3 2021, and its period low was -$87.1 million during Q2 2024.
- Moreover, its 5-year median value for Invested Capital was $23.9 million (2024), whereas its average is $35.1 million.
- Per our database at Business Quant, Seres Therapeutics' Invested Capital surged by 33310.19% in 2021 and then tumbled by 51598.81% in 2023.
- Over the past 5 years, Seres Therapeutics' Invested Capital (Quarter) stood at $131.5 million in 2021, then crashed by 91.8% to $10.8 million in 2022, then tumbled by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024, then soared by 217.01% to $43.7 million in 2025.
- Its last three reported values are $43.7 million in Q3 2025, $32.9 million for Q2 2025, and $50.5 million during Q1 2025.